FIELD: medicine, biotechnology.
SUBSTANCE: invention relates to soluble mutant CTLA4 molecules that bind with antigen CD86 with high avidity than with CTLA4 of wild type. Invention involves both different mutant forms and fused proteins wherein the constant region of immunoglobulin is used as the second amino acid sequence, and nucleic acid molecule encoding CTLA4, complementary DNA, and plasmid comprising complementary DNA are used also. Invention relates also to a method for regulation of interaction of functional CTLA4-positive T cells with CD80 and CD86-positive cells and method for suppression of response reaction "transplant against host". The advantage of invention involves enhancing activity of these mutant forms due to improvement of avidity.
EFFECT: valuable biological properties of CTLA4 molecules.
26 cl, 1 tbl, 7 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLUBLE MUTANT CTLA4 AND USES THEREOF | 2001 |
|
RU2283847C2 |
| METHODS FOR TREATMENT OF RHEUMATIC DISEASES BY USING SOLUBLE CTLA4 | 2001 |
|
RU2287340C2 |
| IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS | 2008 |
|
RU2506275C2 |
| NUCLEIC ACIDS, CODING RECEPTOR CTLA-4 OF CAT, VECTORS, HOST CELLS, VACCINES, OLIGONUCLEOTIDES, POLYPEPTIDES CTLA-4 OF CAT AND METHODS FOR INDUCTION AND SUPPRESSION OF IMMUNE RESPONSE IN CAT | 1999 |
|
RU2377302C2 |
| ISOLATED NUCLEIC ACID ENCODING FELINE LIGAND CD86, DIAGNOSTIC OLIGONUCLEOTIDE, CLONING VECTOR, VACCINE, METHODS FOR INDUCTION OR SUPPRESSION OF IMMUNITY IN CAT | 1999 |
|
RU2263145C2 |
| THERAPEUTIC USE OF INHIBITORS OF T-CELL ACTIVATION OR STIMULATION | 2016 |
|
RU2779308C2 |
| INHIBITORS OF T-CELL ACTIVATION | 2012 |
|
RU2657440C2 |
| CTLA-4 VARIANTS | 2013 |
|
RU2671465C2 |
| HUMANIZED MONOCLONAL ANTIBODY RAISED AGAINST AILIM, CO-STIMULATING MOLECULE FOR SIGNAL TRANSFER AND ITS PHARMACEUTICAL APPLYING | 2001 |
|
RU2262511C2 |
| PHARMACEUTICAL COMPOSITION FOR IMMUNE DISEASE TREATMENT | 2000 |
|
RU2203682C2 |
